How to Measure Cell Proliferation: Techniques & Assay Comparison

Promega Corporation

Publication date: 2026

Abstract


Cell proliferation, the process of cell growth and division, is a fundamental parameter in cell-based research. Because changes in proliferation are among the earliest indicators that a treatment is affecting cell behavior, proliferation assays are used routinely across drug discovery, cancer biology, immunology and cell therapy to screen compounds, validate targets and evaluate therapeutic responses. Five, well-established measurement approaches for cell proliferation exist: metabolic activity assays, DNA synthesis, immunodetection of proliferation markers, dye dilution and DNA content quantification. Each has distinct strengths and trade-offs in terms of throughput, specificity, workflow complexity and whether it measures proliferation directly or infers it from a surrogate readout.

No-wash luminescent immunoassays that detect the nuclear proliferation marker Ki-67 have emerged as a sixth approach, offering a reliable, proliferation-specific readout in a fast, easy add-mix-measure protocol. This guide compares each method, discusses their advantages and limitations, and provides a framework for selecting the best assay for your experimental needs.

Why Is Measuring Cell Proliferation Important?

Measuring cell proliferation is fundamental across biomedical research. Whether a cell population is growing, arrested or declining is one of the earliest and most informative readouts of how cells are responding to their environment; a drug treatment, a genetic perturbation, a growth factor stimulus or a change in culture conditions. At the most basic level, monitoring proliferation is part of routine cell culture: confirming expected doubling times, tracking growth consistency across passages and flagging potential issues such as genetic drift, phenotypic change or contamination. Beyond routine culture maintenance, proliferation is also one of the most common experimental readouts in cell-based studies. If a treatment changes proliferation, further investigation is warranted, making proliferation assays a staple from early-stage compound screening through late-stage mechanism-of-action work.

Drug discovery and toxicology

Proliferation assays are workhorses in early drug screening. They show whether a compound inhibits cell growth and help rank hits for further development. Screening against antiproliferative targets depends on reliable proliferation readouts to triage compounds quickly. Proliferation assays also play a central role in safety and toxicology profiling, where they monitor whether drug candidates have unintended effects on cell growth in non-target cell populations.

Targeted therapeutics and biologics

Targeted protein degradation, or using PROTACs or molecular glues to selectively destroy disease-causing proteins, is one of the fastest-growing areas in drug discovery. Proliferation assays confirm that degrading the target protein translates into a functional cellular outcome: cells stop growing. Similarly, antibody-drug conjugates (ADCs) that deliver cytotoxic payloads to specific cell types rely on proliferation readouts to verify that the payload is reaching its target and stopping those cells from dividing. In both cases, proliferation is the downstream confirmation that the therapeutic mechanism is working as intended.

Immunology and cell therapy

Lymphocyte proliferation, particularly T-cell activation and clonal expansion, is a key measure of immune function. In immuno-oncology, proliferation matters on both sides of the equation: researchers want tumor cells to stop proliferating and immune cells to start. Proliferation assays are used to quantify T-cell activation, assess CAR-T cell expansion during manufacturing and screen immune modulators for their ability to enhance or suppress immune cell growth.

Cancer biology and mechanistic studies

Uncontrolled proliferation is a defining hallmark of cancer. Measuring how fast tumor cells divide, how they respond to therapy, and whether oncogenic mutations (such as those in the RAS pathway) drive accelerated growth are central questions in oncology research. Beyond cancer, proliferation assays are used to dissect the molecular pathways that govern cell division, including cell cycle regulation, growth factor signaling and checkpoint controls.

Proliferation vs. Viability: A Critical Distinction

Proliferation refers specifically to cells actively dividing: progressing through the cell cycle and producing daughter cells. Viability indicates that cells are alive and metabolically active. Many commonly used “proliferation assays” actually measure viability (live cell number) and infer proliferation from changes in that number over time. This approach assumes that viability signal is proportional to cell number — an assumption that holds in many routine experiments. However, certain experimental conditions can break that assumption. Treatments that arrest the cell cycle without killing cells, for example, leave viability signals largely unchanged even though proliferation has stopped. When the question is specifically whether cells are dividing, rather than whether they are alive, an assay that directly measures a parameter of cell division will give a more definitive answer.

Choosing an assay that matches the biological question you are asking is essential for generating meaningful data, but the question isn't the only factor. Throughput requirements and available instrumentation also shape which method is practical for your lab. The sections below compare five established categories of proliferation assays plus a newer no-wash luminescent immunoassay approach. At the end of this guide, we provide a framework for weighing these factors together to choose the assay that works best for you.

Metabolic Activity Assays

Metabolic activity assays are the most widely used approach for estimating cell proliferation in plate-based formats. They measure enzymatic activity in live cells as an indirect proxy for the number of viable, metabolically active cells in a well. Typically, this involves the reduction of a substrate by mitochondrial dehydrogenases or related enzymes. In most assays, a reagent is added to cells in culture and live cells enzymatically convert the reagent into a detectable product. The major subcategories of metabolic activity proliferation assays are:

Tetrazolium reduction assays (MTT, MTS, XTT, WST-1):

Living cells reduce tetrazolium salts via NAD(P)H-dependent dehydrogenases to produce colored formazan products. MTT forms an insoluble purple formazan requiring a solubilization step; MTS and WST-1 yield soluble products that can be read directly. Our CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) provides a convenient one-step add-incubate-read colorimetric protocol, while the CellTiter 96® Non-Radioactive Cell Proliferation Assay offers an MTT-based option.

Resazurin reduction assays:

The blue, non-fluorescent dye resazurin is reduced by viable cells to pink, fluorescent resorufin. CellTiter-Blue® Cell Viability Assay uses this approach and is compatible with fluorescence or absorbance readouts.

ATP-based bioluminescent assays:

These use the firefly luciferase reaction, where light output is directly proportional to ATP content—and therefore to the number of viable cells. CellTiter-Glo® Luminescent Cell Viability Assay is the most widely cited assay in this class, offering extremely high sensitivity, broad dynamic range, and a simple add-lyse-read protocol.

Real-time metabolic assays:

RealTime-Glo™ MT Cell Viability Assay uses a non-lytic, continuous-read luminescent chemistry that enables kinetic monitoring of cell viability over hours or days—in the same wells, without sacrificing samples at each time point.

Advantages

  • Simple, often homogeneous (add-and-read) protocols
  • High throughput: compatible with 96-, 384- and 1536-well formats
  • High sensitivity (especially ATP-luminescent assays)
  • No specialized equipment beyond a plate reader
  • Cost-effective
  • Some formats allow non-destructive kinetic monitoring

Limitations

  • Indirect: measures metabolism, not cell division itself
  • Can be confounded by changes in per-cell metabolic activity (e.g., compounds that affect mitochondrial function or ATP metabolism)
  • Cannot distinguish cytostatic (growth arrest) from cytotoxic effects
  • Most formats are endpoint (lytic), except continuous-monitoring variants

Note on CDK inhibitors: Cells treated with CDK4/6 inhibitors stop dividing but often continue to grow in size, maintaining or even increasing metabolic activity. In these cases, metabolic activity assays may show no decrease, or even an increase, in signal, masking the antiproliferative effect (learn more about this concept in our blog). A readout more directly tied to proliferative state (such as a Ki-67 marker assay, DNA synthesis, or DNA content) will detect the antiproliferative effect that metabolic assays can miss. This scenario is particularly relevant in oncology drug screening as CDK inhibitors are a common therapeutic class.

Best Suited For:

General viability screening; high-throughput drug discovery; routine cell culture monitoring; applications where viability and proliferation are tightly coupled; cost-sensitive, high-volume experiments.

DNA Synthesis Assays

DNA synthesis assays directly measure the production of new DNA during S-phase, making them specific for cells that are actively replicating their genomes. These assays incorporate labeled nucleoside analogs into newly synthesized DNA, then detect the incorporated label.

The three types of DNA synthesis assays are:

[³H]-Thymidine incorporation: The classic gold standard. Cells incorporate radioactive thymidine during DNA replication; the amount of radioactivity in harvested DNA is measured by scintillation counting. While highly sensitive, radioactive handling and disposal requirements have driven a shift toward non-radioactive alternatives.

BrdU (5-bromo-2′-deoxyuridine): A thymidine analog incorporated into replicating DNA. After a labeling period, cells are fixed and the incorporated BrdU is detected with an anti-BrdU antibody. Detection requires DNA denaturation (to expose the BrdU epitope) followed by antibody staining, a multi-step protocol.

EdU (5-ethynyl-2′-deoxyuridine): A newer thymidine analog detected by copper-catalyzed click chemistry rather than antibodies. This eliminates the need for DNA denaturation, resulting in faster staining with lower background.

Advantages

  • Direct measure of DNA replication, specific for dividing cells
  • Single-cell resolution by microscopy or flow cytometry
  • Can be combined with cell cycle DNA stains for phase analysis
  • EdU click chemistry offers faster detection than BrdU
  • Well-established, widely published methods

Limitations

  • Multi-step protocols: fixation, permeabilization, staining, washes
  • Labor-intensive; less amenable to high-throughput screening
  • Endpoint only, cells are fixed and cannot be reused
  • BrdU requires harsh DNA denaturation for antibody access
  • Radioactive formats ([³H]-thymidine) require special handling
  • Pulse timing must be optimized to capture S-phase window

Best Suited For:

Confirming cell cycle arrest (S-phase entry); immunology experiments measuring lymphocyte proliferation; studies requiring single-cell resolution of which cells divided; combining proliferation data with cell cycle phase analysis by flow cytometry; microscopy-based spatial proliferation studies in tissues.

Immunodetection of Proliferation Markers

Rather than labeling newly synthesized DNA, this approach detects endogenous proteins that are specifically expressed in proliferating cells. The most widely used marker is Ki-67, a nuclear protein present in all active phases of the cell cycle (G1, S, G2 and M) but absent in quiescent (G0) cells. Other markers include PCNA (proliferating cell nuclear antigen) and phospho-histone H3 (Ser10), which marks cells in mitosis.

Cells or tissue sections are fixed, permeabilized and incubated with a primary antibody against the proliferation marker. A labeled secondary antibody then enables detection by microscopy, flow cytometry or enzyme-linked immunoassay.

Advantages

  • Specific to proliferating cells (Ki-67 is absent in G0)
  • No exogenous label needed, detects natural protein expression
  • Provides spatial context in tissue sections (IHC)
  • Can be multiplexed with other markers (cell type, activation state)
  • Applicable to both cultured cells and tissue samples

Limitations

  • Multi-step: fix, permeabilize, block, antibody incubations, washes
  • Endpoint method, requires cell fixation
  • Low throughput (microscopy) or moderate throughput (flow)
  • Antibody quality and staining consistency affect results
  • Semi-quantitative without automated image analysis or flow

Best Suited For:

Identifying which cells in a mixed population are proliferating; combining proliferation with phenotypic markers by flow cytometry; validating cell cycle exit or entry in mechanistic studies: tissue section analysis where spatial context matters.

Dye Dilution and Generational Analysis

Dye dilution assays are the method of choice when researchers need to know how many times individual cells have divided. By labeling cells with a fluorescent dye that partitions equally between daughter cells at each division, flow cytometry can resolve discrete generations within a population.

How They Work

Cells are loaded with a stable fluorescent dye, commonly CFSE (carboxyfluorescein succinimidyl ester) or CellTrace™ Violet, that binds covalently to intracellular proteins. As cells divide, each daughter inherits approximately half the dye, producing a halving of fluorescence intensity per generation. After culture under experimental conditions, cells are analyzed by flow cytometry. The resulting histogram shows a series of peaks, each representing one additional round of division.

Advantages

  • Resolves individual generations (typically 6–8 divisions)
  • Single-cell resolution of division history
  • Reveals heterogeneity: which cells divided and how many times
  • Can be combined with surface markers to identify proliferating subsets
  • Standard in immunology for T-cell activation and clonal expansion studies

Limitations

  • Requires a flow cytometer and expertise in flow analysis
  • Not plate-reader compatible, lower throughput than plate-based assays
  • Dye concentration must be optimized (too much is toxic; too little gives poor resolution)
  • Fluorescence fades below detection after many divisions
  • Forward-tracking only: cells must be labeled before the experiment

Best Suited For:

T-cell activation and lymphocyte proliferation studies; tracking clonal expansion in heterogeneous immune cell populations; cell therapy manufacturing QC (assessing expansion capacity); any experiment where the number of divisions per cell is the key question; combining division tracking with immunophenotyping by flow cytometry.

No-Wash Luminescent Immunoassay for hKi-67 Detection

As noted in the sections above, each established proliferation method involves a trade-off between specificity, workflow complexity and throughput. The Lumit® Cell Proliferation Assay (Human Ki-67) was designed to address these trade-offs by delivering a reliable, proliferation-specific readout in a fast, no-wash plate-based format.

How It Works

The assay uses two antibodies against human Ki-67, each conjugated to a complementary fragment of a split luciferase (NanoBiT® technology). When both antibodies bind hKi-67 protein in a cell lysate, the luciferase fragments reconstitute, producing a luminescent signal proportional to hKi-67 levels. Because signal is generated only when both antibody fragments are brought into proximity by the target, no wash steps are needed to separate bound from unbound antibodies. The workflow is add-mix-measure: lyse cells, add the antibody-substrate reagent and read luminescence on a standard plate reader.

Line graph showing highly linear luminescence response (r²=0.998) across Jurkat cell titration in a 96-well plate format using the Lumit® Cell Proliferation Assay (Human Ki-67).
Bar graph showing strong luminescence signal in wild-type HeLa cells and near-zero signal in Ki-67 knockout and no-cell controls, demonstrating specific hKi-67 detection using the Lumit® Cell Proliferation Assay (Human Ki-67).
Line graph showing highly linear luminescence response (r²=0.992) across Jurkat cell titration in a 384-well plate format using the Lumit® Cell Proliferation Assay (Human Ki-67).

Advantages

  • Proliferation-specific: Ki-67 is present only in actively cycling cells
  • No wash steps, homogeneous add-mix-read format
  • Results in under 2 hours; minimal hands-on time
  • Independent of metabolic state; not confounded by metabolic shifts
  • Pronounced signal changes at early time points
  • Standard plate reader (luminescence), no flow cytometer or microscope required
  • Compatible with 96- and 384-well formats for screening
  • Can be multiplexed with a membrane-integrity dye to distinguish antiproliferative from cytotoxic effects

Limitations

  • Bulk measurement (average Ki-67 per well), no single-cell data
  • Endpoint: requires cell lysis
  • Does not report number of divisions (only proliferative state)

Best Suited For:

Screening compounds for antiproliferative activity and evaluating proliferative responsiveness to stimulatory agents; confirming cell cycle arrest in mechanism-of-action studies; quantifying T-cell proliferation in a plate-based format; detecting early proliferation changes before cell number diverges; replacing labor-intensive protocols; complementing viability assays to distinguish cytostatic vs. cytotoxic responses.

Assay Comparison Table

The table below provides a side-by-side comparison of the five established proliferation assay categories plus the luminescent hKi-67 immunoassay. Use it to quickly identify which method best matches your experimental requirements.

Method What It Measures Wash Steps Time Throughput Equipment
Metabolic Activity (MTT, MTS, ATP, resazurin) Enzymatic activity / ATP of viable cells, reducing potential None 10 min – 4 h High Plate reader
DNA Synthesis (BrdU, EdU, [³H]-thymidine) New DNA in S-phase cells Multiple 4 – 8 h Low – moderate Plate reader, microscope or flow cytometer
Immunodetection (Ki-67 IHC/ICC, PCNA, pH3) Proliferation-associated proteins Multiple 6 – 24 h Low Plate reader, microscope or flow cytometer
Dye Dilution (CFSE, CellTrace™) Division count per cell (dye halving) Initial label wash Days + 1 h analysis Low – moderate Flow cytometer
DNA Content (CyQUANT, PI staining) Total DNA per well (proxy for cell number) Varies 1 – 3 h Moderate-high Plate reader or flow cytometer
Lumit® Cell Proliferation Assay (Human Ki-67) hKi-67 protein in cell lysate None < 2 h High Plate reader
Table 1. Comparison of cell proliferation measurement methods. “Direct” indicates the assay measures a parameter specific to cell division (not inferred from viability). The Lumit Ki-67 row is highlighted to show its unique combination of direct measurement, no wash steps, fast protocol, and plate-based high throughput.